Search the Newsreel

Small Cap Watch: D3 Energy, Astral Resources, Surefire and Dalaroo advance company programs

Small Cap Watch: D3 Energy, Astral Resources, Surefire and Dalaroo advance company programs Proactive uses images sourced from Shutterstock The S&P/ASX Small Ordinaries (ASX: XSO) finished Friday at 3,517.10 points, down 24.30 points or 0.69% for the session. Over the past five trading days, …

Why STAAR Surgical (STAA) Is Up 8.1% After Q2 Profit Rebound And New CEO Appointment

STAAR Surgical (STAA) Gives Warren Foust The CEO Role After Its Profit Reset

STAAR Surgical has appointed Warren Foust as its permanent President and CEO, following a period of operational reset and a return to profitable growth under his interim leadership. Foust's promotion from COO and interim co-CEO signifies a defined leadership direction for the ophthalmic device …

STAAR Surgical (STAA) Stock May Be 13% Below Fair Value Following Q2 Earnings Preview

Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA

Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the …

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

AAR (AIR) Stock Looks Strong On Returns While Trading At A Premium

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AAR has delivered very strong share price returns over the past five years, yet its current valuation checks lean expensive rather than like a clear bargain. With …

Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen

Wall Street Zen upgraded Aardvark Therapeutics (NASDAQ:AARD) from "strong sell" to "sell," while the broader analyst consensus on MarketBeat remains a "hold" with a $16.30 price target. The clinical-stage biopharmaceutical company, specializing in treatments for autoimmune and inflammatory diseases, reported a quarterly loss of …

Aarey Drugs & Pharmaceuticals standalone net profit declines 25.55% in the June 2026 quarter

Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors

Staar Surgical Co (STAA) shares surged 3.4% to $26.19, with a GF Score of 80/100, indicating strong overall performance. The stock is considered "Modestly Undervalued" by GuruFocus, with a potential upside of 21.8% from its current price, although its high P/E ratio and lack …

Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 8

Staar Surgical Co (STAA) shares surged 3.4% to $26.19, with a GF Score of 80/100, indicating strong overall performance. The stock is considered "Modestly Undervalued" by GuruFocus, with a potential upside of 21.8% from its current price, although its high P/E ratio and lack …

Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action

Robbins LLP has filed a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who purchased shares during its February 13, 2025 IPO or between February 13, 2025 and May 14, 2026. The lawsuit alleges that Aardvark misled investors regarding …

Aarvi Encon net profit up 43% in Q1FY27; EBITDA margin slips to 2.61%

AAR (AIR) Wins FAA Approval, Is The Stock Fully Priced?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AAR (AIR) is back on investors' radar after becoming the first third party maintenance, repair, and overhaul provider approved by the FAA for Safety Management System Requirements. …

STAAR Surgical (STAA) reports 8.4% stake held by Madison Avenue group

A group of investment entities associated with Eli Samaha, collectively known as the Madison Avenue group, has reported a beneficial ownership of 8.4% in STAAR Surgical Company (STAA) as of June 30, 2026. This stake represents 4,175,748 shares of Common Stock out of 49,788,495 …

Aartech Solonics Ltd Forms Golden Cross Amid Mixed Technical Signals and Improving Momentum

Aartech Solonics Q1 Results: Net profit up 62% YoY to ₹155.26 lakh

Aarvi Encon declares ₹2 per share final dividend for FY26

Aarvi Encon Limited schedules 33rd AGM on August 14, 2026

UBS Adjusts Price Target on STAAR Surgical to $19 From $20, Keeps Sell Rating

UBS has adjusted its price target for STAAR Surgical Company (STAA) to $19, down from $20, while maintaining a Sell rating on the stock. This update reflects the analyst's current outlook on the medical equipment company. The article also notes recent company activities including …

STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates

STAAR Surgical reported a strong Q2 2026, returning to profit with $8.1 million in net income and $93.5 million in sales, largely driven by significant growth in China. Despite these positive results, the stock price barely moved, reflecting investor concerns about the company's heavy …

Jefferies cuts STAAR Surgical stock price target on estimate update

Jefferies has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $28 from $29, while maintaining a Hold rating, following the company's second-quarter 2026 results. STAAR Surgical reported Q2 revenue of $93.5 million, beating consensus estimates, with strong China sales, but missed earnings per …

STAAR Surgical Company Q2 2026 Earnings Call Summary

STAAR Surgical reported record first-half revenue, driven by the successful launch of EVO Plus in China, which helped gain market share despite a challenging refractive market. The company is strategically shifting to a platform approach, with plans for new product development and a transition …

STAAR Surgical Company Stock 12‑Month Price Target Cut to $28.89, Implies 14% Upside

STAAR Surgical Company's average 12-month price target has been reduced to $28.89 from $29.33, according to estimates from 9 analysts. This updated target suggests a potential upside of approximately 14% based on the August 12 closing price. The consensus rating for the stock remains …

Piper Sandler reiterates Neutral on STAAR Surgical stock at $33

Piper Sandler reiterated a Neutral rating on STAAR Surgical (NASDAQ:STAA) with a $33.00 price target, following the company's second-quarter results. While STAAR Surgical's China business exceeded expectations, generating $52.3 million in revenue, the company missed revenue expectations in other key regions like the United …

STAAR Surgical (NASDAQ:STAA) Shares Gap Down Following Analyst Downgrade

STAAR Surgical (NASDAQ:STAA) Price Target Lowered to $37.00 at Wedbush

Wedbush has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $37.00 from $40.00 but maintained an "outperform" rating, indicating a potential upside of 45.61%. Despite this, analyst sentiment is mixed, with an average "hold" rating and a consensus price target of $26.61. The …

JHS Svendgaard Retail Ventures reports standalone net profit of Rs 0.24 crore in the June 2026 quarter

STAAR Surgical earnings beat by $0.02, revenue topped estimates

Aartech Solonics consolidated net profit rises 63.54% in the June 2026 quarter

JHS Svendgaard Retail Ventures subscribes to ₹5 Cr OCDs of Purple Rock Infra

STAAR Surgical: China Generates More Than Half Of Q2 Revenue As Total Sales Jump 111%

STAAR Surgical reported a 111% year-over-year jump in Q2 2026 net sales to $93.5 million, with China contributing over half of this revenue at $52.3 million. The company saw significant profitability improvements, including a gross margin increase to 74.5% and net income of $8.1 …

JHS Svendgaard Retail appoints Sood and Pathak as independent directors